<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To enhance the in vivo antitumor activity of adoptively transferred, CD19-specific chimeric antigen receptor (CAR)-redirected cytotoxic T lymphocytes (CTLs), we studied the effect of restimulating CAR(+) CTLs through their endogenous virus-specific T-cell antigen receptor (TcR) by the cotransfer of engineered T-cell antigen-presenting cells (T-APCs) </plain></SENT>
<SENT sid="1" pm="."><plain>Using <z:e sem="disease" ids="C0021400" disease_type="Disease or Syndrome" abbrv="FLU">influenza</z:e> A matrix protein 1 (MP1) as a model antigen, we show that ex vivo-expanded CD4(+) and CD8(+) T-APCs expressing a <z:chebi fb="0" ids="24753">hygromycin</z:chebi> phosphotransferase-MP1 fusion protein (HyMP1) process and present MP1 to autologous human leukocyte antigen (HLA)-restricted, MP1-specific CD4(+) and CD8(+) CTL precursors </plain></SENT>
<SENT sid="2" pm="."><plain>The MP1-specific CTLs are amenable to subsequent genetic modification to express a CD19-specific CAR, designated CD19R, and acquire HLA-unrestricted reactivity toward CD19(+) <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:hpo ids='HP_0002665'>lymphoma</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> targets while maintaining HLA-restricted MP1 specificity </plain></SENT>
<SENT sid="3" pm="."><plain>The restimulation of MP1xCD19 dual-specific CTLs in vivo by the adoptive transfer of irradiated HyMP1(+) T-APCs resulted in the enhanced antilymphoma potency of bispecific effector cells, as measured by elimination of the biophotonic signal of established firefly luciferase-expressing Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> xenografts in nonobese diabetic/<z:hpo ids='HP_0004430'>severe combined immunodeficiency</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NOD</z:e>/scid) animals compared with control groups restimulated by Hy(+)MP1(neg) T-APCs </plain></SENT>
<SENT sid="4" pm="."><plain>Engineered T-APCs are a novel and versatile antigen-delivery system for generating antigen-specific T cells in vitro and enhancing the in vivo effector functioning of CAR-redirected antitumor effector cells </plain></SENT>
</text></document>